Majaya, EvidenceGirdler-Brown, B.V. (Brendan)Muchengeti, MazvitaSingh, Elvira2022-04-082022-04-082021-01Majaya, E., Girdler-Brown, B.V., Muchengeti, M. et al. 2021, 'The impact of the South African antiretroviral treatment programme on the age-standardised incidence rate of Kaposi sarcoma, 1999-2016: An interrupted time series analysis', International Journal of Infectious Diseases, vol. 102, pp. 20-27.1201-9712 (print)1878-3511 (online)htt11016/j.ijid.2020.10.020http://hdl.handle.net/2263/84849OBJECTIVE : The objective of this study was to quantify the impact of the South African antiretroviral treatment programme on the age-standardised incidence rate of Kaposi sarcoma among black South African residents of all ages. METHODS : We performed an interrupted time series analysis using routinely collected, histologically confirmed surveillance data from the South African National Cancer Registry for the years 1999 to 2016. The analysis was performed using R statistical software. The total number of cases was 29,623 (12,475 females and 17,166 males). The background antiretroviral treatment coverage was less than 1% at the time that the antiretroviral programme was introduced and increased to over 50% in 2016. RESULTS : In 1999, the age-standardised rates were 1.48 and 2.82 cases per 100,000 per year for black females and males, respectively. These rates increased to 5.52 and 7.46 in 2008 before declining. The antiretroviral treatment programme was started in 2004. Five years after 2008 (nine years after the antiretroviral programme was introduced), the predicted standardised rates were 58.3% and 50.3% lower for females and males, respectively, than what they would have been without the treatment programme. CONCLUSION : Introduction of the antiretroviral treatment programme was associated with a decrease of over 50% in the predicted age-standardised incidence rates of Kaposi sarcoma. © 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.en© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license.Kaposi sarcomaAntiretroviral therapy (ART)Interrupted time series analysis (ITSA)Article